<html>
<head>
<title>Section 415:18-y Oral Anti-Cancer Therapies.</title>
<!-- Hide metadata
<titlename>TITLE XXXVII INSURANCE</titlename>
<chapter>CHAPTER 415 ACCIDENT AND HEALTH INSURANCE</chapter>
<sectiontitle>Section 415:18-y Oral Anti-Cancer Therapies.</sectiontitle>
-->
<meta name="titlename" content="TITLE XXXVII INSURANCE">
<meta name="chapter" content="CHAPTER 415 ACCIDENT AND HEALTH INSURANCE">
<meta name="sectiontitle" content="Section 415:18-y Oral Anti-Cancer Therapies.">
<meta name="sourcenote" content="Source.  2015, 263:7, eff. Jan. 1, 2017.">
<meta name="codesect" content="<br>&nbsp&nbsp&nbspI. No insurer that issues or renews any policy of group or blanket accident or health insurance providing benefits for anti-cancer medications that are injected or intravenously administered by a health care provider and patient administered anti-cancer medications, including but not limited to those orally administered or self-injected, shall require a higher copayment, deductible, or coinsurance amount for patient administered anti-cancer medication than it requires for injected or intravenously administered anti-cancer medications, regardless of the formulation or benefit category determination by the policy or plan.<br>&nbsp&nbsp&nbspII. An insurer shall not comply with paragraph I by:<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(a) Increasing the copayment, deductible, or coinsurance amount required for injected or intravenously administered anti-cancer medication that are covered under the policy or plan.<br>&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp(b) Reclassifying benefits with respect to anti-cancer medications.<br>&nbsp&nbsp&nbspIII. In this section, anti-cancer medication'' means drugs and biologics that are used to kill, slow, or prevent the growth of cancerous cells.<br>&nbsp&nbsp&nbspIV. If the cost-sharing requirements for orally administered anti-cancer medications do not exceed $200 per prescription fill, the health plan shall be deemed in compliance with this section.<br>&nbsp&nbsp&nbspV. For a health care contract that meets the definition of a high deductible plan'' set forth in 26 U.S.C. section 223(c)(2), a carrier shall be exempt from the provisions of paragraphs I-IV until an enrollee's deductible has been satisfied for the year.<br>&nbsp&nbsp&nbspVI. This section shall apply only to oral anti-cancer medications where an intravenously administered or injected anti-cancer medication is not medically appropriate.<br>&nbsp&nbsp&nbspVII. This section shall not apply to policies which are solely to replace income or pay a predetermined fixed amount based on the occurrence of a specified medical or health event.">
</head>
<body>
<center><h1>TITLE XXXVII<br>INSURANCE</h1></center>
<center><h2>CHAPTER 415<br>ACCIDENT AND HEALTH INSURANCE</h2></center>
<center><h3>Section 415:18-y</h3></center>
<br><center>[RSA 415:18-y effective January 1, 2017, and repealed by 2015, 263:14, II, effective January 1, 2021.]</center>
&nbsp;&nbsp;&nbsp;<b> 415:18-y Oral Anti-Cancer Therapies. &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
I. No insurer that issues or renews any policy of group or blanket accident or health insurance providing benefits for anti-cancer medications that are injected or intravenously administered by a health care provider and patient administered anti-cancer medications, including but not limited to those orally administered or self-injected, shall require a higher copayment, deductible, or coinsurance amount for patient administered anti-cancer medication than it requires for injected or intravenously administered anti-cancer medications, regardless of the formulation or benefit category determination by the policy or plan.
<br>
&nbsp&nbsp&nbsp
II. An insurer shall not comply with paragraph I by:
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(a) Increasing the copayment, deductible, or coinsurance amount required for injected or intravenously administered anti-cancer medication that are covered under the policy or plan.
<br>
&nbsp&nbsp&nbsp&nbsp&nbsp&nbsp
(b) Reclassifying benefits with respect to anti-cancer medications.
<br>
&nbsp&nbsp&nbsp
III. In this section, "anti-cancer medication'' means drugs and biologics that are used to kill, slow, or prevent the growth of cancerous cells.
<br>
&nbsp&nbsp&nbsp
IV. If the cost-sharing requirements for orally administered anti-cancer medications do not exceed $200 per prescription fill, the health plan shall be deemed in compliance with this section.
<br>
&nbsp&nbsp&nbsp
V. For a health care contract that meets the definition of a "high deductible plan'' set forth in 26 U.S.C. section 223(c)(2), a carrier shall be exempt from the provisions of paragraphs I-IV until an enrollee's deductible has been satisfied for the year.
<br>
&nbsp&nbsp&nbsp
VI. This section shall apply only to oral anti-cancer medications where an intravenously administered or injected anti-cancer medication is not medically appropriate.
<br>
&nbsp&nbsp&nbsp
VII. This section shall not apply to policies which are solely to replace income or pay a predetermined fixed amount based on the occurrence of a specified medical or health event.
</codesect>
<sourcenote>
<p><b>Source.</b>  2015, 263:7, eff. Jan. 1, 2017.</p>
</sourcenote>
</body>
</html>
